NexGel Highlights Positive Data From Proof-of-Concept Study For Its Diclofenac Hydrogel Pain Treatment

NexGel Inc NXGL announced results from its proof-of-concept study for its diclofenac hydrogel patches.
The patches are designed to treat pain indications such as arthritis, joint pain, muscle aches, and more.
The study compared NexGel's diclofenac hydrogel patches with the leading commercially available topical treatment.
It assessed the formulations, skin retention, and permeation of the products through the skin. The results revealed that NexGel's diclofenac hydrogel patches delivered an equivalent dose considerably faster and are longer-acting compared to the current standard of care on a head-to-head basis.
They also showed gentle skin adhesion for eight to 12 hours.
Diclofenac patches are nonsteroidal anti-inflammatory drug (NSAIDs) products used to treat short-term pain due to minor strains, sprains, and bruises.
The early proof-of-concept results validate the potential effectiveness of NexGel's technology in drug delivery patches.
Last week, NexGel said it had developed a new, proprietary hydrogel eye patch to treat amblyopia, a type of poor vision that typically occurs in one eye but can occur in both eyes (also called lazy eye).
The patch is expected to be available for ophthalmologists and optometrists to offer to their patients in 1H of 2023.
Price Action: NXGL shares are trading flat at $1.35 on the last check Tuesday.